[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-411022-105":59,"doc-detail-411022-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pediatric-acute-lymphoblastic-leukemia-relapse-and-prognosis-key-predictors-and-therapeutic-implications","Pediatric acute lymphoblastic leukemia relapse and prognosis key predictors and therapeutic implications","","Pediatric acute lymphoblastic leukemia relapse is associated with poor outcomes, making identification of relapse risk essential for treatment planning. The document reports analysis of clinical and biological predictors, including immunophenotype and measurable residual disease dynamics, and evaluates how these factors relate to event-free survival and overall survival. It also describes treatment-related considerations and discusses how risk stratification may inform therapeutic decisions and follow-up strategies for relapsed pediatric ALL.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pediatric-acute-lymphoblastic-leukemia-relapse-and-prognosis-key-predictors-and-therapeutic-implications/411022/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pediatric-acute-lymphoblastic-leukemia-relapse-and-prognosis-key-predictors-and-therapeutic-implications/411022.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What outcomes are used to assess prognosis in pediatric ALL relapse?","Question",{"text":113,"@type":114},"The document uses event-free survival (EFS) and overall survival (OS) to evaluate prognosis and relate predictors to patient outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which biological/clinical factors are highlighted as relapse predictors?",{"text":118,"@type":114},"Key predictors discussed include immunophenotype patterns and measurable residual disease-related variables, assessed alongside survival endpoints.",{"name":120,"@type":111,"acceptedAnswer":121},"How can the findings influence therapeutic decisions for relapsed pediatric ALL?",{"text":122,"@type":114},"The document emphasizes that identifying relapse predictors and risk categories can support treatment planning, therapeutic intensity considerations, and follow-up strategy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},411022,1790798759,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":4},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","T􀀘􀀁E O􀀎􀀐􀀇􀀐􀀆􀀒􀀓 􀀜􀀃􀀖􀀃􀀒􀀎􀀑􀀍  \n􀀁UB􀀛ISHED 18 D􀀃􀀑􀀃􀀚b􀀃􀀎 2025 DOI 10.3389/fp􀀃􀀄 .2025.1710578  \n􀀁􀀂􀀃􀀄􀀁􀀂 􀀆􀀇  \n􀀁􀀂􀀃􀀄􀀅􀀆􀀇 􀀉􀀂􀀊  \n􀀋􀀅􀀂􀀌􀀍􀀃􀀎􀀆 􀀏􀀃􀀄􀀐􀀑􀀒􀀓 􀀔􀀆􀀐􀀕􀀃􀀎􀀖􀀐􀀌􀀗􀀊 􀀘􀀍􀀐􀀆􀀒  \n􀀈􀀁􀀉􀀃􀀁􀀊􀀁􀀂 􀀆􀀇  \n􀀙􀀐􀀒􀀑􀀅􀀚􀀅 􀀙􀀅􀀌􀀌􀀐􀀊  \n􀀛􀀜􀀘􀀘􀀋 􀀋􀀒􀀆 􀀙􀀃􀀎􀀒􀀎􀀄􀀅 􀀄􀀃􀀐 􀀝􀀐􀀆􀀌􀀅􀀎􀀐 􀀞􀀅􀀂􀀆􀀄􀀒􀀌􀀐􀀅􀀆􀀊􀀛􀀌􀀒􀀓􀀗  \n􀀃􀀃 Y􀀅􀀂􀀆􀀇 J􀀂􀀊  \n􀀋􀀂􀀆􀀇k􀀗􀀂􀀆kw􀀒􀀆 􀀔􀀆􀀐􀀕􀀃􀀎􀀖􀀐􀀌􀀗􀀊 􀀜􀀃p􀀂b􀀓􀀐􀀑 􀀅f K􀀅􀀎􀀃􀀒  \n*􀀋􀀌􀀈􀀈􀀁􀀍􀀎􀀌􀀏􀀂􀀁􀀏􀀋􀀁  \n􀀉􀀃􀀐N􀀒 Z􀀍􀀒􀀆􀀇  \n zw􀀆18@126 .􀀑􀀅􀀚  \n􀀈􀀁􀀋􀀁􀀃􀀉􀀁􀀂 22 􀀋􀀃p􀀌􀀃􀀚b􀀃􀀎 2025  \n􀀈􀀁􀀉􀀃􀀍􀀁􀀂 20 N􀀅􀀕􀀃􀀚b􀀃􀀎 2025  \n􀀐􀀋􀀋􀀁􀀎􀀄􀀁􀀂 03 D􀀃􀀑􀀃􀀚b􀀃􀀎 2025  \n􀀎􀀑􀀆􀀒􀀃􀀍􀀓􀀁􀀂 18 D􀀃􀀑􀀃􀀚b􀀃􀀎 2025  \n􀀋􀀃􀀄􀀐􀀄􀀃􀀌􀀏  \n􀀘􀀍􀀃􀀆 􀀁Y􀀊 􀀉􀀂 LL􀀊 K􀀂􀀒􀀆􀀇 􀀘Y􀀊 􀀉􀀒􀀆􀀇 JY􀀊 􀀒􀀅 􀀉􀀙􀀊 J􀀐􀀒􀀆􀀇 􀀒􀀆􀀄 Z􀀍􀀒􀀆􀀇 􀀉N (2025) P􀀃􀀄􀀐􀀒􀀌􀀎􀀐􀀑 􀀒􀀑􀀂􀀌􀀃􀀓􀀗􀀚p􀀍􀀅b􀀓􀀒􀀖􀀌􀀐􀀑 􀀓􀀃􀀂k􀀃􀀚􀀐􀀒 􀀎􀀃􀀓􀀒p􀀖􀀃 􀀒􀀆􀀄 p􀀎􀀅􀀇􀀆􀀅􀀖􀀐􀀖: k􀀃􀀗 p􀀎􀀃􀀄􀀐􀀑􀀌􀀅􀀎􀀖 􀀒􀀆􀀄 􀀌􀀍􀀃􀀎􀀒p􀀃􀀂􀀌􀀐􀀑􀀐􀀚p􀀓􀀐􀀑􀀒􀀌􀀐􀀅􀀆􀀖 .  \n􀀞􀀎􀀅􀀆􀀌 . P􀀃􀀄􀀐􀀒􀀌􀀎 . 13:1710578 .  \n􀀄􀀅􀀐: 10.3389/fp􀀃􀀄 .2025.1710578  \n􀀋􀀌􀀎􀀇􀀈􀀃􀀔􀀓􀀄  \n© 2025 􀀘􀀍􀀃􀀆􀀊 􀀉􀀂􀀊 K􀀂􀀒􀀆􀀇􀀊 􀀉􀀒􀀆􀀇􀀊 􀀒􀀅􀀊 J􀀐􀀒􀀆􀀇􀀒􀀆􀀄 Z􀀍􀀒􀀆􀀇 . 􀀝􀀍􀀐􀀖 􀀐􀀖 􀀒􀀆 􀀅p􀀃􀀆-􀀒􀀑􀀑􀀃􀀖􀀖 􀀒􀀎􀀌􀀐􀀑􀀓􀀃􀀄􀀐􀀖􀀌􀀎􀀐b􀀂􀀌􀀃􀀄 􀀂􀀆􀀄􀀃􀀎 􀀌􀀍􀀃 􀀌􀀃􀀎􀀚􀀖 􀀅f 􀀌􀀍􀀃 􀀘􀀎􀀃􀀒􀀌􀀐􀀕􀀃􀀘􀀅􀀚􀀚􀀅􀀆􀀖 A􀀌􀀌􀀎􀀐b􀀂􀀌􀀐􀀅􀀆 L􀀐􀀑􀀃􀀆􀀖􀀃 (􀀘􀀘 BY) . 􀀝􀀍􀀃􀀂􀀖􀀃􀀊 􀀄􀀐􀀖􀀌􀀎􀀐b􀀂􀀌􀀐􀀅􀀆 􀀅􀀎 􀀎􀀃p􀀎􀀅􀀄􀀂􀀑􀀌􀀐􀀅􀀆 􀀐􀀆 􀀅􀀌􀀍􀀃􀀎 f􀀅􀀎􀀂􀀚􀀖 􀀐􀀖 p􀀃􀀎􀀚􀀐􀀌􀀌􀀃􀀄􀀊 p􀀎􀀅􀀕􀀐􀀄􀀃􀀄 􀀌􀀍􀀃 􀀅􀀎􀀐􀀇􀀐􀀆􀀒􀀓􀀒􀀂􀀌􀀍􀀅􀀎(􀀖) 􀀒􀀆􀀄 􀀌􀀍􀀃 􀀑􀀅p􀀗􀀎􀀐􀀇􀀍􀀌 􀀅w􀀆􀀃􀀎(􀀖) 􀀒􀀎􀀃􀀑􀀎􀀃􀀄􀀐􀀌􀀃􀀄 􀀒􀀆􀀄 􀀌􀀍􀀒􀀌 􀀌􀀍􀀃 􀀅􀀎􀀐􀀇􀀐􀀆􀀒􀀓 p􀀂b􀀓􀀐􀀑􀀒􀀌􀀐􀀅􀀆 􀀐􀀆􀀌􀀍􀀐􀀖 j􀀅􀀂􀀎􀀆􀀒􀀓 􀀐􀀖 􀀑􀀐􀀌􀀃􀀄􀀊 􀀐􀀆 􀀒􀀑􀀑􀀅􀀎􀀄􀀒􀀆􀀑􀀃 w􀀐􀀌􀀍􀀒􀀑􀀑􀀃p􀀌􀀃􀀄 􀀒􀀑􀀒􀀄􀀃􀀚􀀐􀀑 p􀀎􀀒􀀑􀀌􀀐􀀑􀀃 . N􀀅 􀀂􀀖􀀃􀀊􀀄􀀐􀀖􀀌􀀎􀀐b􀀂􀀌􀀐􀀅􀀆 􀀅􀀎 􀀎􀀃p􀀎􀀅􀀄􀀂􀀑􀀌􀀐􀀅􀀆 􀀐􀀖 p􀀃􀀎􀀚􀀐􀀌􀀌􀀃􀀄 w􀀍􀀐􀀑􀀍 􀀄􀀅􀀃􀀖 􀀆􀀅􀀌 􀀑􀀅􀀚p􀀓􀀗 w􀀐􀀌􀀍 􀀌􀀍􀀃􀀖􀀃 􀀌􀀃􀀎􀀚􀀖 .  \n􀀁􀀂􀀃􀀄􀀅􀀆􀀇􀀄􀀈 􀀅􀀈􀀊􀀆􀀂 􀀋􀀌􀀍􀀎􀀏􀀐􀀑􀀋􀀅􀀒􀀆􀀄􀀈􀀋􀀂􀀊􀀓􀀂􀀍􀀄􀀅 􀀇􀀂􀀋􀀅􀀎􀀒􀀂 􀀅􀀔􀀃 􀀎􀀇􀀐􀀕􀀔􀀐􀀒􀀄􀀒􀀖􀀓􀀂􀀌 􀀎􀀇􀀂􀀃􀀄􀀈􀀆􀀐􀀇􀀒 􀀅􀀔􀀃 􀀆􀀏􀀂􀀇􀀅􀀎􀀂􀀊􀀆􀀄􀀈􀀄􀀍􀀎􀀋􀀄􀀈􀀅􀀆􀀄􀀐􀀔􀀒  \n􀀗􀀄􀀅􀀐􀀘􀀅􀀔 􀀙􀀏􀀂􀀔􀀚 􀀛􀀄􀀔􀀕􀀛􀀄􀀔􀀕 􀀜􀀊􀀚 􀀙􀀅􀀄􀀘􀀊􀀔 􀀝􀀊􀀅􀀔􀀕􀀚 􀀞􀀄􀀅􀀘􀀄 􀀜􀀅􀀔􀀕􀀚􀀜􀀂􀀔 􀀂 H􀀅􀀐􀀚 H􀀊􀀅 􀀞􀀄􀀅􀀔􀀕 􀀅􀀔􀀃 􀀜􀀂􀀄N􀀅 Z􀀏􀀅􀀔􀀕 *  \nD􀀃p􀀒􀀎􀀌􀀚􀀃􀀆􀀌 􀀅f 􀀃􀀚􀀒􀀌􀀅􀀓􀀅􀀇􀀗 􀀒􀀆􀀄 O􀀆􀀑􀀅􀀓􀀅􀀇􀀗􀀊 􀀙􀀂􀀒􀀆􀀇z􀀍􀀅􀀂 􀀉􀀅􀀚􀀃􀀆 􀀒􀀆􀀄 􀀘􀀍􀀐􀀓􀀄􀀎􀀃􀀆’􀀖 􀀏􀀃􀀄􀀐􀀑􀀒􀀓 􀀘􀀃􀀆􀀌􀀃􀀎􀀊􀀙􀀂􀀒􀀆􀀇z􀀍􀀅􀀂 􀀏􀀃􀀄􀀐􀀑􀀒􀀓 􀀔􀀆􀀐􀀕􀀃􀀎􀀖􀀐􀀌􀀗􀀊 􀀙􀀂􀀒􀀆􀀇z􀀍􀀅􀀂􀀊 􀀘􀀍􀀐􀀆􀀒  \n􀀆􀀕􀀖􀀗􀀘􀀙􀀚􀀛􀀜􀀝􀀞 P􀀃􀀄􀀐􀀒􀀌􀀎􀀐􀀑 􀀒􀀑􀀂􀀌􀀃 􀀓􀀗􀀚p􀀍􀀅b􀀓􀀒􀀖􀀌􀀐􀀑 􀀓􀀃􀀂k􀀃􀀚􀀐􀀒 (ALL)􀀊 􀀌􀀍􀀃 􀀚􀀅􀀖􀀌 􀀑􀀅􀀚􀀚􀀅􀀆􀀑􀀍􀀐􀀓􀀄􀀍􀀅􀀅􀀄 􀀚􀀒􀀓􀀐􀀇􀀆􀀒􀀆􀀑􀀗􀀊 􀀒􀀑􀀍􀀐􀀃􀀕􀀃􀀖 >95% 5-􀀗􀀃􀀒􀀎 􀀖􀀂􀀎􀀕􀀐􀀕􀀒􀀓 w􀀐􀀌􀀍 􀀎􀀐􀀖k-􀀒􀀄􀀒p􀀌􀀃􀀄 􀀌􀀍􀀃􀀎􀀒p􀀐􀀃􀀖 . N􀀅􀀆􀀃􀀌􀀍􀀃􀀓􀀃􀀖􀀖􀀊 10%–15% 􀀅f p􀀒􀀌􀀐􀀃􀀆􀀌􀀖 􀀃xp􀀃􀀎􀀐􀀃􀀆􀀑􀀃 􀀎􀀃􀀓􀀒p􀀖􀀃􀀊 w􀀐􀀌􀀍 p􀀅􀀖􀀌-􀀎􀀃􀀓􀀒p􀀖􀀃 􀀖􀀂􀀎􀀕􀀐􀀕􀀒􀀓\u003C50% . 􀀘􀀍􀀒􀀓􀀓􀀃􀀆􀀇􀀃􀀖 􀀎􀀃􀀚􀀒􀀐􀀆 􀀐􀀆 􀀅p􀀌􀀐􀀚􀀐z􀀐􀀆􀀇 􀀚􀀐􀀆􀀐􀀚􀀒􀀓 􀀎􀀃􀀖􀀐􀀄􀀂􀀒􀀓 􀀄􀀐􀀖􀀃􀀒􀀖􀀃 (􀀏􀀜D)-􀀇􀀂􀀐􀀄􀀃􀀄􀀖􀀌􀀎􀀒􀀌􀀃􀀇􀀐􀀃􀀖 􀀒􀀆􀀄 􀀖􀀒􀀓􀀕􀀒􀀇􀀃 􀀌􀀍􀀃􀀎􀀒p􀀐􀀃􀀖 􀀐􀀆 ALL.  \n􀀐 ms􀀞 􀀝􀀍􀀐􀀖 􀀖􀀌􀀂􀀄􀀗 􀀒􀀐􀀚􀀃􀀄 􀀌􀀅 􀀐􀀄􀀃􀀆􀀌􀀐f􀀗 􀀎􀀃􀀓􀀒p􀀖􀀃 p􀀎􀀃􀀄􀀐􀀑􀀌􀀅􀀎􀀖 􀀒􀀆􀀄 􀀒􀀖􀀖􀀃􀀖􀀖 p􀀅􀀖􀀌-􀀎􀀃􀀓􀀒p􀀖􀀃􀀅􀀂􀀌􀀑􀀅􀀚􀀃􀀖 􀀒􀀚􀀅􀀆􀀇 436 p􀀃􀀄􀀐􀀒􀀌􀀎􀀐􀀑 ALL p􀀒􀀌􀀐􀀃􀀆􀀌􀀖 􀀌􀀎􀀃􀀒􀀌􀀃􀀄 􀀒􀀑􀀑􀀅􀀎􀀄􀀐􀀆􀀇 􀀌􀀅 􀀌􀀍􀀃 􀀘􀀘􀀘􀀙 -ALL-2015 p􀀎􀀅􀀌􀀅􀀑􀀅􀀓 .  \n􀀈es􀀛lts􀀞 Of 􀀌􀀍􀀃 436 􀀃􀀆􀀎􀀅􀀓􀀓􀀃􀀄 p􀀒􀀌􀀐􀀃􀀆􀀌􀀖 (􀀚􀀃􀀄􀀐􀀒􀀆 􀀒􀀇􀀃: 3 . 9 􀀗􀀃􀀒􀀎􀀖; 92 .4% B-ALL)􀀊􀀖􀀐x􀀌􀀗-f􀀅􀀂􀀎 p􀀒􀀌􀀐􀀃􀀆􀀌􀀖 (14.7%) 􀀎􀀃􀀓􀀒p􀀖􀀃􀀄􀀊 p􀀎􀀃􀀄􀀅􀀚􀀐􀀆􀀒􀀆􀀌􀀓􀀗 w􀀐􀀌􀀍 􀀐􀀖􀀅􀀓􀀒􀀌􀀃􀀄 b􀀅􀀆􀀃 􀀚􀀒􀀎􀀎􀀅w 􀀐􀀆􀀕􀀅􀀓􀀕􀀃􀀚􀀃􀀆􀀌 (71 . 9%) . 􀀛􀀆􀀄􀀃p􀀃􀀆􀀄􀀃􀀆􀀌 p􀀎􀀃􀀄􀀐􀀑􀀌􀀅􀀎􀀖 􀀐􀀆􀀑􀀓􀀂􀀄􀀃􀀄 􀀌􀀍􀀎􀀅􀀚b􀀅􀀑􀀗􀀌􀀅p􀀃􀀆􀀐􀀒 􀀒􀀌􀀄􀀐􀀒􀀇􀀆􀀅􀀖􀀐􀀖 (O􀀜 = 2 . 09􀀊 􀀁 = 0 . 037)􀀊 􀀃􀀄􀀅􀀆􀀆􀀇􀀃􀀈􀀉(+) (O􀀜 = 3 . 85􀀊 􀀁 = 0 . 024)􀀊 􀀒􀀆􀀄 p􀀅􀀖􀀐􀀌􀀐􀀕􀀃 􀀏􀀜D 􀀅􀀆 􀀄􀀒􀀗 19 (O􀀜 = 2 . 09) 􀀒􀀆􀀄 􀀄􀀒􀀗 46 (O􀀜 = 5 .73􀀊 􀀁 \u003C 0 . 001) 􀀅f 􀀐􀀆􀀄􀀂􀀑􀀌􀀐􀀅􀀆 􀀌􀀍􀀃􀀎􀀒p􀀗 . P􀀅􀀖􀀌-􀀎􀀃􀀓􀀒p􀀖􀀃􀀊 􀀐􀀖􀀅􀀓􀀒􀀌􀀃􀀄 􀀃x􀀌􀀎􀀒􀀚􀀃􀀄􀀂􀀓􀀓􀀒􀀎􀀗 􀀑􀀒􀀖􀀃􀀖 􀀖􀀍􀀅w􀀃􀀄 􀀍􀀐􀀇􀀍􀀃􀀎 O􀀋 (100% 􀀕􀀖 . 72. 9%􀀊 􀀁 = 0 . 078) 􀀌􀀍􀀒􀀆 b􀀅􀀆􀀃 􀀚􀀒􀀎􀀎􀀅w 􀀎􀀃􀀓􀀒p􀀖􀀃􀀖 . 􀀋􀀘􀀝 􀀖􀀐􀀇􀀆􀀐fi􀀑􀀒􀀆􀀌􀀓􀀗􀀐􀀚p􀀎􀀅􀀕􀀃􀀄 O􀀋 􀀐􀀆 b􀀅􀀆􀀃 􀀚􀀒􀀎􀀎􀀅w 􀀎􀀃􀀓􀀒p􀀖􀀃 􀀑􀀅􀀚p􀀒􀀎􀀐􀀆􀀇 􀀌􀀅 p􀀒􀀌􀀐􀀃􀀆􀀌􀀖 􀀌􀀎􀀃􀀒􀀌􀀃􀀄 w􀀐􀀌􀀍􀀑􀀍􀀃􀀚􀀅􀀌􀀍􀀃􀀎􀀒p􀀗 􀀅􀀎 􀀘A􀀜-􀀝 􀀒􀀓􀀅􀀆􀀃 (82 . 6% 􀀕􀀖 . 38. 1%􀀊 􀀁 = 0 . 027) .  \n􀀋􀀚􀀜􀀖l􀀛s 􀀚􀀜􀀞 􀀝􀀍􀀎􀀅􀀚b􀀅􀀑􀀗􀀌􀀅p􀀃􀀆􀀐􀀒 􀀒􀀌 􀀄􀀐􀀒􀀇􀀆􀀅􀀖􀀐􀀖􀀊 􀀃􀀄􀀅􀀆􀀆􀀇􀀃􀀈􀀉(+)􀀊 􀀒􀀆􀀄 p􀀃􀀎􀀖􀀐􀀖􀀌􀀃􀀆􀀌 􀀏􀀜D 􀀒􀀎􀀃 􀀑􀀎􀀐􀀌􀀐􀀑􀀒􀀓 􀀎􀀃􀀓􀀒p􀀖􀀃 p􀀎􀀃􀀄􀀐􀀑􀀌􀀅􀀎􀀖 . 􀀋􀀘􀀝 􀀎􀀃􀀚􀀒􀀐􀀆􀀖 p􀀐􀀕􀀅􀀌􀀒􀀓 f􀀅􀀎 b􀀅􀀆􀀃 􀀚􀀒􀀎􀀎􀀅w 􀀎􀀃􀀓􀀒p􀀖􀀃 .􀀛􀀆􀀑􀀅􀀎p􀀅􀀎􀀒􀀌􀀐􀀆􀀇 p􀀓􀀒􀀌􀀃􀀓􀀃􀀌 􀀑􀀅􀀂􀀆􀀌􀀖 􀀐􀀆􀀌􀀅 􀀎􀀐􀀖k 􀀖􀀌􀀎􀀒􀀌􀀐fi􀀑􀀒􀀌􀀐􀀅􀀆 􀀒􀀆􀀄 􀀅p􀀌􀀐􀀚􀀐z􀀐􀀆􀀇 􀀏􀀜D-􀀇􀀂􀀐􀀄􀀃􀀄 b􀀎􀀐􀀄􀀇􀀐􀀆􀀇 􀀌􀀍􀀃􀀎􀀒p􀀐􀀃􀀖 􀀚􀀒􀀗 􀀃􀀆􀀍􀀒􀀆􀀑􀀃 􀀅􀀂􀀌􀀑􀀅􀀚􀀃 . 􀀞􀀂􀀌􀀂􀀎􀀃 􀀎􀀃􀀖􀀃􀀒􀀎􀀑􀀍 􀀖􀀍􀀅􀀂􀀓􀀄 p􀀎􀀐􀀅􀀎􀀐􀀌􀀐z􀀃 􀀌􀀍􀀎􀀅􀀚b􀀅􀀑􀀗􀀌􀀅p􀀃􀀆􀀐􀀒 􀀚􀀃􀀑􀀍􀀒􀀆􀀐􀀖􀀚􀀖 􀀒􀀆􀀄 􀀋􀀘􀀝 p􀀎􀀃􀀑􀀅􀀆􀀄􀀐􀀌􀀐􀀅􀀆􀀐􀀆􀀇 􀀖􀀌􀀎􀀒􀀌􀀃􀀇􀀐􀀃􀀖 .  \nK􀀁􀀇􀀊􀀌􀀈􀀂􀀍  \n􀀕􀀖􀀛te lymph􀀚bl􀀕st 􀀖 le􀀛􀀗em 􀀕, mm􀀛􀀜􀀚the􀀕􀀙py, pe􀀝 􀀕t􀀙 􀀖, p􀀙􀀚􀀘􀀜􀀚s s, 􀀙el􀀕pse  \n1 I􀀔􀀆􀀇􀀐􀀃􀀊􀀈􀀆􀀄􀀐􀀔  \n􀀁􀀂􀀃􀀄􀀅 􀀇􀀈􀀉􀀊􀀋􀀌􀀍􀀇􀀎􀀏􀀄􀀐􀀂 􀀇􀀅􀀃􀀑􀀅􀀉􀀐􀀎 􀀒􀀁􀀓􀀓􀀔􀀕 􀀄􀀋􀀅 􀀉􀀌􀀏􀀄 􀀂􀀌􀀉􀀉􀀌􀀖 􀀊􀀅􀀗􀀐􀀎􀀄􀀘􀀐􀀂 􀀉􀀎􀀇􀀐􀀙􀀖􀀎􀀖􀀂􀀈􀀕 􀀋􀀎􀀏􀀃􀀖􀀗􀀅􀀘􀀙􀀌􀀖􀀅 􀀄􀀘􀀎􀀖􀀏􀀚􀀌􀀘􀀉􀀎􀀄􀀐􀀛􀀅 􀀐􀀉􀀊􀀘􀀌􀀛􀀅􀀉􀀅􀀖􀀄􀀏 􀀐􀀖 􀀏􀀃􀀘􀀛􀀐􀀛􀀎􀀇 􀀄􀀋􀀘􀀌􀀃􀀙􀀋 􀀘􀀐􀀏􀀑􀀜􀀏􀀄􀀘􀀎􀀄􀀐􀀝􀀅􀀗 􀀄􀀘􀀅􀀎􀀄􀀉􀀅􀀖􀀄􀀊􀀘􀀌􀀄􀀌􀀂􀀌􀀇􀀏􀀞 􀀃􀀘􀀘􀀅􀀖􀀄 􀀄􀀋􀀅􀀘􀀎􀀊􀀅􀀃􀀄􀀐􀀂 􀀏􀀄􀀘􀀎􀀄􀀅􀀙􀀐􀀅􀀏 􀀎􀀂􀀋􀀐􀀅􀀛􀀅 5􀀜􀀈􀀅􀀎􀀘 􀀅􀀛􀀅􀀖􀀄􀀜􀀚􀀘􀀅􀀅 􀀏􀀃􀀘􀀛􀀐􀀛􀀎􀀇 􀀒EFS􀀔 􀀘􀀎􀀄􀀅􀀏􀀌􀀚 􀀌􀀛􀀅􀀘 85% 􀀎􀀖􀀗 􀀌􀀛􀀅􀀘􀀎􀀇􀀇 􀀏􀀃􀀘􀀛􀀐􀀛􀀎􀀇 􀀒OS􀀔 􀀘􀀎􀀄􀀅􀀏 􀀎􀀊􀀊􀀘􀀌􀀎􀀂􀀋􀀐􀀖􀀙 95% 􀀒1–3􀀔􀀞 N􀀅􀀛􀀅􀀘􀀄􀀋􀀅􀀇􀀅􀀏􀀏􀀕􀀎􀀊􀀊􀀘􀀌x􀀐􀀉􀀎􀀄􀀅􀀇􀀈 10% 􀀌􀀚 􀀊􀀅􀀗􀀐􀀎􀀄􀀘􀀐􀀂 􀀁􀀓􀀓 􀀊􀀎􀀄􀀐􀀅􀀖􀀄􀀏 􀀅x􀀊􀀅􀀘􀀐􀀅􀀖􀀂􀀅 􀀘􀀅􀀇􀀎􀀊􀀏􀀅􀀕 􀀎􀀖􀀗 􀀊􀀌􀀏􀀄􀀜􀀘􀀅􀀇􀀎􀀊􀀏􀀅 OS 􀀊􀀇􀀃􀀉􀀉􀀅􀀄􀀏 􀀄􀀌 􀀍􀀅􀀇􀀌w 50% 􀀒4􀀔􀀞 I􀀗􀀅􀀖􀀄􀀐􀀚􀀈􀀐􀀖􀀙 􀀘􀀐􀀏􀀑 􀀚􀀎􀀂􀀄􀀌􀀘􀀏 􀀎􀀏􀀏􀀌􀀂􀀐􀀎􀀄􀀅􀀗 w􀀐􀀄􀀋 􀀘􀀅􀀇􀀎􀀊􀀏􀀅 􀀎􀀖􀀗􀀘􀀅􀀗􀀃􀀂􀀐􀀖􀀙 􀀘􀀅􀀇􀀎􀀊􀀏􀀅 􀀐􀀖􀀂􀀐􀀗􀀅􀀖􀀂􀀅 􀀘􀀅􀀉􀀎􀀐􀀖 􀀂􀀘􀀃􀀂􀀐􀀎􀀇 􀀊􀀘􀀐􀀌􀀘􀀐􀀄􀀐􀀅􀀏 􀀚􀀌􀀘 􀀌􀀊􀀄􀀐􀀉􀀐z􀀐􀀖􀀙 􀀄􀀘􀀅􀀎􀀄􀀉􀀅􀀖􀀄􀀚􀀘􀀎􀀉􀀅w􀀌􀀘􀀑􀀏􀀞 P􀀘􀀅􀀏􀀅􀀖􀀄 􀀏􀀄􀀘􀀎􀀄􀀅􀀙􀀐􀀅􀀏 􀀚􀀌􀀂􀀃􀀏 􀀌􀀖 􀀘􀀅􀀝􀀖􀀐􀀖􀀙 􀀘􀀐􀀏􀀑 􀀏􀀄􀀘􀀎􀀄􀀐􀀝􀀂􀀎􀀄􀀐􀀌􀀖􀀕 􀀅􀀖􀀋􀀎􀀖􀀂􀀐􀀖􀀙 􀀉􀀐􀀖􀀐􀀉􀀎􀀇  \nF􀀇􀀐􀀔􀀆􀀄􀀂􀀇􀀒 􀀄􀀔 􀀁􀀂􀀃􀀄􀀅􀀆􀀇􀀄􀀈􀀒 01 f􀀇􀀐􀀔􀀆􀀄􀀂􀀇􀀒􀀄􀀔 .􀀐􀀇􀀕  \n􀀘􀀅􀀏􀀐􀀗􀀃􀀎􀀇 􀀗􀀐􀀏􀀅􀀎􀀏􀀅 􀀒MRD􀀔􀀜􀀙􀀃􀀐􀀗􀀅􀀗 􀀐􀀖􀀄􀀅􀀘􀀛􀀅􀀖􀀄􀀐􀀌􀀖􀀏􀀕 􀀎􀀖􀀗 􀀐􀀖􀀂􀀌􀀘􀀊􀀌􀀘􀀎􀀄􀀐􀀖􀀙􀀖􀀌􀀛","cbCaigH8RHSeyIHz","https://ap.wps.com/l/cbCaigH8RHSeyIHz","pdf",379463,"English","# Key predictors of relapse and outcomes\n## Measurable residual disease and survival associations\n## Risk factors and treatment implications\n## Clinical subgroup patterns","[{\"question\":\"What outcomes are used to assess prognosis in pediatric ALL relapse?\",\"answer\":\"The document uses event-free survival (EFS) and overall survival (OS) to evaluate prognosis and relate predictors to patient outcomes.\"},{\"question\":\"Which biological/clinical factors are highlighted as relapse predictors?\",\"answer\":\"Key predictors discussed include immunophenotype patterns and measurable residual disease-related variables, assessed alongside survival endpoints.\"},{\"question\":\"How can the findings influence therapeutic decisions for relapsed pediatric ALL?\",\"answer\":\"The document emphasizes that identifying relapse predictors and risk categories can support treatment planning, therapeutic intensity considerations, and follow-up strategy.\"}]","Pediatric acute lymphoblastic leukemia relapse and prognosis key predictors and therapeutic implications | PDF",1790587115]